Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Tremfya bests Cosentyx in psoriasis study 

By Brian Buntz | September 21, 2021

JanssenJanssen’s Tremfya (guselkumab) generally had higher efficacy in treating moderate-to-severe psoriasis than Cosentyx (secukinumab) from Novartis, according to recent data published in the Journal of Dermatological Treatment. 

In the 48-week Phase 3 ECLIPSE study, a greater number of guselkumab recipients achieved at least a 90% and 100% improvement from baseline in Psoriasis Area and Severity Index (PASI 90 and PASI 100). Guselkumab recipients also had higher rates of clear or almost clear skin based on the Investigator’s Global Assessment scores of IGA 0 and IGA 0/1, respectively

The difference in performance between the two drugs was especially pronounced in patients weighing more than 100 kg (220 pounds). For instance, 62.3% of guselkumab recipients weighing 100–110 kg had IGA 0/1 responses at week 48, while 44.4% of secukinumab recipients did. 

The findings are significant because people with psoriasis have a higher prevalence and incidence of obesity than the general public, said Dr. Lloyd Miller, vice president, immunodermatology disease area leader at Janssen. 

Psoriasis involves systemic inflammation that can trigger a cascade of responses, leading to an increased risk of conditions ranging from metabolic syndrome to arthritis. 

“Psoriasis goes beyond skin deep,” Miller said. Psoriasis patients have elevated levels of inflammatory mediators in their blood. 

“We know there are long term effects of having all this background inflammation” associated with psoriasis, Miller said. 

The fact that Tremfya is effective in many heavier patients is important because “obesity can also affect the patient’s response to treatment,” Miller said. 


Filed Under: clinical trials, Dermatology, Drug Discovery, Immunology
Tagged With: Cosentyx, guselkumab, Janssen, Novartis, psoriasis, secukinumab, Tremfya
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

AbbVie
AbbVie’s Skyrizi becomes first drug to win FDA nod for Crohn’s disease
Eli Lilly in the Drug Discovery & Development Pharma 50
FDA approves Olumiant as first systemic therapy for baldness form 
Epsolay-Galderma-Sol-Gel
FDA approves first microencapsulated benzoyl peroxide for rosacea
Eli Lilly
Lilly’s lebrikizumab with topical corticosteroids improved atopic dermatitis in the study

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50